Telehealth company Hims & Hers cancels $49 monthly weight loss drug launch following FDA warnings about unapproved semaglutide compounds and Novo threats.Read More
Hims & Hers responds to FDA pressure, pulls knockoff Wegovy drug launch after regulatory threats
By Brie Stimson
